Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
22 JPY | -15.38% | -.--% | -4.35% |
Apr. 29 | Poland's Tusk calls prosecutor over potential Orlen scandal | RE |
Apr. 22 | OncoTherapy Science, Inc. cancelled the transaction announced on April 5, 2024 | CI |
Sales 2022 | 1.15B 7.33M | Sales 2023 | 1.13B 7.2M | Capitalization | 9.05B 57.52M |
---|---|---|---|---|---|
Net income 2022 | -2.57B -16.33M | Net income 2023 | -1.12B -7.1M | EV / Sales 2022 | 9.94 x |
Net cash position 2022 | 1.84B 11.66M | Net cash position 2023 | 1.12B 7.1M | EV / Sales 2023 | 7 x |
P/E ratio 2022 |
-5.03
x | P/E ratio 2023 |
-8.1
x | Employees | 60 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 83.13% |
1 day | -15.38% | ||
Current month | +29.41% | ||
1 month | +29.41% | ||
3 months | -4.35% | ||
6 months | -12.00% | ||
Current year | -4.35% |
Managers | Title | Age | Since |
---|---|---|---|
Junichi Shimada
PSD | President | 63 | 21-11-30 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 17-06-30 |
Yuichi Komine
BRD | Director/Board Member | 52 | 08-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Yuichi Komine
BRD | Director/Board Member | 52 | 08-05-31 |
Zehyon Paku
CTO | Chief Tech/Sci/R&D Officer | 48 | 17-06-30 |
Hatsuo Kato
CHM | Chairman | 80 | 20-05-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-31 | 22 | -15.38% | 20,073,200 |
24-05-30 | 26 | -13.33% | 11,040,500 |
24-05-29 | 30 | -.--% | 42,199,700 |
24-05-28 | 30 | +3.45% | 30,796,900 |
24-05-27 | 29 | -12.12% | 44,477,800 |
Delayed Quote Japan Exchange, May 31, 2024 at 02:00 am EDT
More quotes1st Jan change | Capi. | |
---|---|---|
-4.35% | 39.72M | |
+11.91% | 114B | |
+11.60% | 105B | |
-4.68% | 23.83B | |
-0.82% | 21.73B | |
-10.12% | 18.1B | |
-42.12% | 16.34B | |
-17.47% | 16.13B | |
+2.77% | 13.75B | |
+34.58% | 11.76B |
- Stock Market
- Equities
- 4564 Stock